Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes
The use of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, particularly in lung cancer. However, their use in patients with pre-existing autoimmune diseases (PADs) presents unique challenges. PADs, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and pso...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1539260/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328056614780928 |
|---|---|
| author | Hui Yang Hui Yang Sheng Yu Sheng Yu Hong Ge Hong Ge |
| author_facet | Hui Yang Hui Yang Sheng Yu Sheng Yu Hong Ge Hong Ge |
| author_sort | Hui Yang |
| collection | DOAJ |
| description | The use of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, particularly in lung cancer. However, their use in patients with pre-existing autoimmune diseases (PADs) presents unique challenges. PADs, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis, complicate the clinical management of lung cancer due to concerns about worsening autoimmune symptoms during ICI therapy. This review summarized the safety and efficacy of ICIs in lung cancer patients with PAD, focusing on the available clinical evidence, the optimal timing of ICI initiation, and the potential predictive biomarkers for immune-related adverse events (irAEs). Future prospective studies are needed to establish definitive guidelines for the use of ICIs in this population, with a focus on identifying patients at risk, managing ICI resumption after irAE and developing new medications with durable control of both cancer and PAD. |
| format | Article |
| id | doaj-art-6e7c370d96eb4c1ca37eeb14e8e051e2 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-6e7c370d96eb4c1ca37eeb14e8e051e22025-08-20T03:47:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15392601539260Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomesHui Yang0Hui Yang1Sheng Yu2Sheng Yu3Hong Ge4Hong Ge5Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaLaboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaLaboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaLaboratory of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, ChinaThe use of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, particularly in lung cancer. However, their use in patients with pre-existing autoimmune diseases (PADs) presents unique challenges. PADs, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis, complicate the clinical management of lung cancer due to concerns about worsening autoimmune symptoms during ICI therapy. This review summarized the safety and efficacy of ICIs in lung cancer patients with PAD, focusing on the available clinical evidence, the optimal timing of ICI initiation, and the potential predictive biomarkers for immune-related adverse events (irAEs). Future prospective studies are needed to establish definitive guidelines for the use of ICIs in this population, with a focus on identifying patients at risk, managing ICI resumption after irAE and developing new medications with durable control of both cancer and PAD.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1539260/fulllung cancerimmune checkpoint inhibitors (ICBs)immune-related adverse events (IRAE)autoimmune disease (AD)flarepredictive biomarker |
| spellingShingle | Hui Yang Hui Yang Sheng Yu Sheng Yu Hong Ge Hong Ge Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes Frontiers in Immunology lung cancer immune checkpoint inhibitors (ICBs) immune-related adverse events (IRAE) autoimmune disease (AD) flare predictive biomarker |
| title | Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes |
| title_full | Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes |
| title_fullStr | Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes |
| title_full_unstemmed | Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes |
| title_short | Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes |
| title_sort | leveraging immune checkpoint inhibitors in lung cancer patients with pre existing autoimmune disease clinical insights optimal timing and predictive biomarkers for optimal treatment outcomes |
| topic | lung cancer immune checkpoint inhibitors (ICBs) immune-related adverse events (IRAE) autoimmune disease (AD) flare predictive biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1539260/full |
| work_keys_str_mv | AT huiyang leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes AT huiyang leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes AT shengyu leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes AT shengyu leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes AT hongge leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes AT hongge leveragingimmunecheckpointinhibitorsinlungcancerpatientswithpreexistingautoimmunediseaseclinicalinsightsoptimaltimingandpredictivebiomarkersforoptimaltreatmentoutcomes |